PT - JOURNAL ARTICLE AU - Kalkeri, Raj AU - Zhu, Mingzhu AU - Cloney-Clark, Shane AU - Plested, Joyce S. AU - Parekh, Anand AU - Gorinson, Drew AU - Cai, Rongman AU - Mahato, Soham AU - Ramanathan, Pradhipa AU - Aurelia, L. Carissa AU - Selva, Kevin John AU - Marchese, Anthony M. AU - Fries, Louis AU - Chung, Amy W. AU - Dunkle, Lisa M. TI - Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines AID - 10.1101/2024.01.17.24301374 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.17.24301374 4099 - http://medrxiv.org/content/early/2024/01/18/2024.01.17.24301374.short 4100 - http://medrxiv.org/content/early/2024/01/18/2024.01.17.24301374.full AB - Repeated mRNA SARS-CoV-2 vaccination has been associated with increases in the proportion of IgG4 in spike-specific antibody responses and concurrent reductions in Fcγ-mediated effector functions that may limit control of viral infection. Here, we assessed anti-Spike total IgG, IgG1, IgG2, IgG3 and IgG4, and surrogate markers for antibody-dependent cellular phagocytosis (ADCP, FcγRIIa binding), antibody-dependent cellular cytotoxicity (ADCC, FcγRIIIa binding), and antibody-dependent complement deposition (ADCD, C1q binding) associated with repeated SARS-CoV-2 vaccination with NVX-CoV2373 (Novavax Inc., Gaithersburg, MD). The NVX-CoV2373 protein vaccine did not induce notable increases in spike-specific IgG4 or negatively impact surrogates for Fcγ effector responses. Conversely, repeated NVX-CoV2373 vaccination uniquely enhanced IgG3 responses which are known to exhibit strong affinity for FcγRIIIa and have previously been linked to potent neutralization of SARS-CoV-2. Subsequent investigations will help to understand the immunological diversity generated by different SARS-CoV-2 vaccine types and have the potential to reshape public health strategies.Competing Interest StatementR.K., M.Z., S.C-C, J.S.P., A.P., D.G., R.C., S.M., A.M.M., L.F., and L.M.D. are the employees and stockholders of Novavax, Inc. P.R., L.C.A., K.J.S., and A.W.C. are the employees of the Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity. A.W.C. received grant funding from NHMRC, MRFF, and NIH. PR., L.C.A., and K.J.S. declare no conflicts/disclosure information.Clinical TrialNCT04611802 and NCT05463068Funding StatementThis study was funded by Novavax, Inc. Samples from 2019nCoV-301 (ClinicalTrials.gov: NCT04611802) were included in the present study. 2019nCoV-301 was funded by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA; contract Operation Warp Speed: Novavax Project Agreement number 1 under Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium base agreement no. 2020-530; Department of Defense no. W911QY20C0077); and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The NIAID provides grant funding to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center (UM1 AI68614), the HVTN Statistics and Data Management Center (UM1 AI68635), the HVTN Laboratory Center (UM1 AI68618), the HIV Prevention Trials Network Leadership and Operations Center (UM1 AI68619), the AIDS Clinical Trials Group Leadership and Operations Center (UM1 AI68636), and the Infectious Diseases Clinical Research Consortium leadership group (UM1AI148684). Samples from 2019nCoV-307 (ClinicalTrials.gov: NCT05463068) were included in the present study. 2019nCoV-307 was funded by Novavax, Inc. with support from the US BARDA (Contract W15QKN-16-9-1002, Project Number MCDC2011-001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below: for 2019nCoV-307: The study was reviewed, approved and overseen by the Advarra Institutional Review Board, Columbia, MD. for 2019nCoV-301: The following Institutional Review Boards / Independent Ethics committees reviewed and gave ethical approval for the PREVENT-19 study: Western Copernicus Group IRB, US; Great Plains IRB, US; Comite de etica en investigacion del Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico; Comite de etica en investigacion de la Unidad de Atencion Medica e Investigacion en Salud S.C., Mexico; Comite de etica en investigacion del Instituto Nacional de Salud Publica, Mexico; Comite de etica en investigacion de Medica Rio Mayo S.C., Mexico; Comite de etica en investigacion del Hospital La Mision S.A. de C.V., Mexico. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated during and/or analyzed for this publication are not available at this time.